Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues: Implications for dendritic cell vaccines

Nadine Santana-Magal; Leen Farhat-Younis; Yaron Carmi

doi:10.18632/ONCOTARGET.27972

Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues: Implications for dendritic cell vaccines

Nadine Santana-Magal
, Leen Farhat-Younis
, Yaron Carmi

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1631-1633
Number of pages	3
Journal	Oncotarget
Volume	12
Issue number	16
DOIs	https://doi.org/10.18632/ONCOTARGET.27972
State	Published - 3 Aug 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antigen presentation
Dendritic cells
T cells

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/ONCOTARGET.27972

Cite this

@article{6fd4890b34584a599b369b28292122ad,

title = "Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues: Implications for dendritic cell vaccines",

keywords = "Antigen presentation, Dendritic cells, T cells",

author = "Nadine Santana-Magal and Leen Farhat-Younis and Yaron Carmi",

year = "2021",

month = aug,

day = "3",

doi = "10.18632/ONCOTARGET.27972",

language = "English",

volume = "12",

pages = "1631--1633",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "16",

}

TY - JOUR

T1 - Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues

T2 - Implications for dendritic cell vaccines

AU - Santana-Magal, Nadine

AU - Farhat-Younis, Leen

AU - Carmi, Yaron

PY - 2021/8/3

Y1 - 2021/8/3

KW - Antigen presentation

KW - Dendritic cells

KW - T cells

UR - https://www.scopus.com/pages/publications/85112426149

U2 - 10.18632/ONCOTARGET.27972

DO - 10.18632/ONCOTARGET.27972

M3 - Editorial

C2 - 34381569

AN - SCOPUS:85112426149

SN - 1949-2553

VL - 12

SP - 1631

EP - 1633

JO - Oncotarget

JF - Oncotarget

IS - 16

ER -